210 likes | 649 Views
Modeling Childhood-onset Myotonic Dystrophy . Jordan Gladman Ph.D. PRPR 9/24/2012. Myotonic Dystrophy Type 1. Autosomal dominant 1 in 8000 - most common adult muscular dystrophy Variable age of onset and phenotype Congenital Childhood Adult. Common features:.
E N D
Modeling Childhood-onset Myotonic Dystrophy Jordan Gladman Ph.D. PRPR 9/24/2012
Myotonic Dystrophy Type 1 • Autosomal dominant • 1 in 8000 - most common adult muscular dystrophy • Variable age of onset and phenotype • Congenital • Childhood • Adult Common features: • Progressive skeletal muscle loss • Cardiac defects • Smooth muscle dysfunction • Other multisystem effects including cataracts, insulin resistance, mental retardation
Congenital Myotonic Dystrophy • Children often born from mothers with DM1 • Respiratory and swallowing difficulties • moderate to severe intellectual disabilities • cardiomyopathy • Often need extensive neonatal care • Survivors may strengthen somewhat, but ultimately develop a progressive myopathy similar to the more common forms of the disease • Myotonia absent in neonates
Childhood-Onset Myotonic Dystrophy • Milder than congenital myotonic dystrophy but still more severe than Adult DM1 • No parent of origin effect • Unlike congenital myotonic dystrophy individuals with childhood-onset myotonic dystrophy do not have in utero abnormalities, delayed early motor development, and if present only have mild hypotonia or respiratory problems • Childhood-onset DM1 patients usually have myotonia and frequently have mental handicaps such as a decrease in mean IQ and a range of psychosocial difficulties • As patients age they tend to then also develop features seen in adult onset DM1.
Adult Onset Myotonic Dystrophy • Characteristic appearance: • Myotonia • Muscle weakness and wasting • Low IQ/dementia • Cardiac abnormalities • Hypersomnia/fatigue • Multiple endocrinopathies • Gastrointestinal complaints • Cataracts
Disease severity and Repeating numbers (CTG)n DMPK • Disease severity correlated with (CUG)n repeat size. • Age of Onset, Average age of death, disease symptoms
Caused by a CTG expansion in the 3’-UTR of DMPK (CUG)5-37 AUG Stop DMPK RNA AAAA ORF 5’-UTR 3’-UTR mRNA exported and transcribed (CUG)100+ DMPK protein ORF Coiled coil Trans- mem. AAAA LRR Kinase 3’-UTR mRNA Retained in Nucleus
Mouse Models of DM1 • The perfect mouse model, especially to study therapeutics, does not exist • Multiple labs working on addressing this issue • Most efforts are aimed at adult DM1 Goal: Develop a childhood onset mouse model of DM1 that allows therapeutic testing and can be used to better understand DM1
Transgenic Mouse Design rtTA TRANSGENE (Tet-On System) CMV promoter rtTA Dox Dox GFP-DMPK 3’UTR TRANSGENE DMPK 5’UTR 7X TRE 5’UTR GFP DMPK 3’UTR DMPK 1st INTRON Induction of Dox leads to a robust disease phenotype similar to the phenotype seen in patients
Design Birth P P&T P Start induction of the toxic RNA before birth, as early as conception and monitor disease phenotype - Start with the DM5 mice as we have them well characterized - Mate a DM5 +/- who is induced for 1 months with a DM5 -/- - Keep dox present during mating, pregnancy and rearing CHDM1 P&T Adult DM1 weeks 2 4 6 8 16 infancy childhood adolescent adulthood
Generating a Childhood onset DM1 Birth P P A B P&T CHDM1 P&T Adult DM1 weeks 2 4 6 8 16 infancy childhood adolescent adulthood C D
Skeletal muscle pathology present but not as severe as the adult DM1 Control DM1 CHDM1 Adult DM1
Parent of Origin Both sick DM1 sexes produce pups that are equally sick - Like childhood DM1 in humans there does not seem to be a parent of origin effect
Molecular Analysis of CHDM1 mice A WT CHDM1 Cugbp1 Gapdh Mbnl1 -RT +RT Input -RT +RT NTC Beads B IgG EGFP-DM5 UTR CHDM1 Adult DM1 EGFP-DM5 UTR C WT CHDM1
MBNL1 overexpression, a model for therapeutic testing, corrects myotonia MBNL1-EGFP Leg EGFP Leg A C MBNL1-EGFP Mbnl1 B Gapdh CHDM1 CHDM1 D EGFP Mbnl1 EGFP Mbnl1
A Reminder Birth P P A B P&T CHDM1 P&T Adult DM1 weeks 2 4 6 8 16 infancy childhood adolescent adulthood C D
Early presence of pathological levels of toxic RNA leads to a more severe DM1 phenotype, this is independent of repeat length Remember CHDM1 muscle had a milder pathology than adult muscle
Conclusions Future Directions • Expressing the toxic RNA during development leads to a CHDM1 mouse model • This model is more severe than its adult counterpart • It can be used to test therapeutics • Age of onset, independent of repeat length, has an effect on disease phenotype • Complete this work by evaluation more mice • Move into the DM200 mouse mode • Examine neurological phenotype in these mice
Acknowledgements • Dr. Mani S. Mahadevan • Mahua Mandal • Dr. Ramesh Yadava • Dr. Yun Kim • Qing Yu (Jane) • Dr. Erin P. Foff • Dr. Shagufta Rehman Questions?